Top Markets
Coin of the day
BGI Genomics Co., Ltd. BGI Genomics Co., Ltd.

BGI Genomics Co., Ltd.

300676
株式のランク #5740
BGI Genomics Co., Ltd. operates as an international supplier of genetic testing... BGI Genomics Co., Ltd. operates as an international supplier of genetic testing solutions and sequencing services. The company caters to a broad clientele, encompassing medical and research facilities, as well as other public and private organizations, both within China and across the globe. Its comprehensive service portfolio includes DNA, RNA, and tailored sequencing options. Additionally, it offers a suite of specialized genetic tests such as non-invasive prenatal testing (NIPT), reproductive health screening, and newborn genetic screening, alongside clinical exome sequencing. BGI Genomics also develops clinical and research-focused solutions for the field of oncology. During the COVID-19 pandemic, the firm provided crucial laboratory solutions for the detection and diagnosis of suspected cases, including SARS-CoV-2 IgM and IgG antibody detection kits, and real-time fluorescent RT-PCR kits. Their expertise spans numerous research domains, including but not limited to agriculture and food science, cancer research, metagenomics, reproductive health, biomarker discovery, and drug development. Established in 1999, the company initially operated under the name Shenzhen BGI Medicine Co., Ltd. before officially changing to BGI Genomics Co., Ltd. in 2015. Its corporate headquarters are located in Shenzhen, China.
株価
$5.91
時価総額
$2.47B
変化(1日)
0.10%
変化(1年)
-22.57%
CN
取引 BGI Genomics Co., Ltd. (300676)

カテゴリー

BGI Genomics Co., Ltd.(300676)の収益
Aug 2026 時点の収益 TTM: 0
BGI Genomics Co., Ltd. の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
BGI Genomics Co., Ltd. の収益履歴(2026 ~ 2026)
各年末の収益
収益 変化
提供された日付のデータは十分ではありません。
同業他社の収益